Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- 17-alpha-Hydroxypregnenolone blood MeSH
- Depressive Disorder blood MeSH
- Adult MeSH
- Follicular Phase blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Menstrual Cycle blood MeSH
- Osmolar Concentration MeSH
- Pregnenolone blood MeSH
- Steroids blood MeSH
- Anxiety blood MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 17-alpha-Hydroxypregnenolone MeSH
- Pregnenolone MeSH
- pregnenolone sulfate MeSH Browser
- Steroids MeSH
Concentrations of neurosteroids may be influenced by some physiological or pathological factors. We investigated neuroactive steroids in the serum of women suffering from anxiety-depressive disorder treated with fluoxetine and in a control group, in both the follicular and the luteal phases of the menstrual cycle. Two groups of neuroactive steroids were measured by radioimmunoassays: 1) the positive allosteric modulator of GABA(A) receptors, allopregnanolone with its precursor progesterone and 2) pregnenolone sulfate and dehydroepiandrosterone sulfate (DHEAS) acting on GABA(A) receptors by an opposite mechanism. Significantly higher levels of pregnenolone sulfate (p < 0.0001) were found in patients in both phases of the menstrual cycle. Significantly higher values were recorded in pregnenolone (p < 0.001) and 17alpha-hydroxypregnenolone (p < 0.01) levels in the patients group in the follicular phase. Our results indicate that imbalance in neuroactive steroids may play a negative role in origin and course of psychiatric and neurological disorders.
See more in PubMed
Neuroendocrinology. 1998 Feb;67(2):126-38 PubMed
Clin Exp Rheumatol. 1989 Nov-Dec;7(6):583-8 PubMed
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13512-7 PubMed
Am J Psychiatry. 1998 Jul;155(7):910-3 PubMed
Horm Metab Res. 1998 Apr;30(4):227-30 PubMed
Eur J Endocrinol. 2000 Mar;142(3):269-73 PubMed
J Clin Endocrinol Metab. 1983 Sep;57(3):550-6 PubMed
Endocr Rev. 1991 Nov;12(4):372-401 PubMed
Steroids. 1995 Feb;60(2):210-3 PubMed
J Clin Psychopharmacol. 1997 Feb;17(1):11-4 PubMed
FASEB J. 1992 Mar;6(6):2311-22 PubMed
Recent Prog Horm Res. 1997;52:1-32 PubMed
Ann N Y Acad Sci. 1995 Dec 29;774:82-110 PubMed
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12599-604 PubMed
J Neuroendocrinol. 1991 Jun 1;3(3):261-5 PubMed
Biol Psychiatry. 1998 Nov 1;44(9):865-73 PubMed
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3239-44 PubMed
J Steroid Biochem Mol Biol. 1997 Jul;62(4):299-306 PubMed
J Clin Endocrinol Metab. 1996 Mar;81(3):1076-82 PubMed
Nihon Naibunpi Gakkai Zasshi. 1976 Oct 20;52(10):1008-19 PubMed
Neuroendocrinology. 1993 Oct;58(4):478-84 PubMed
Clin Chem Lab Med. 1999 Apr;37(4):439-47 PubMed
